Literature DB >> 32787379

Overview of prognostic factors in adult gliomas.

Akanksha Sharma1, Jerome J Graber2.   

Abstract

Gliomas represent the majority of malignant central nervous system tumors, with the most aggressive subtype, glioblastoma, accounting for almost 57% of this entity. Type of glioma and its incidence can vary depending on the age of presentation. In turn, outcomes can vary significantly based on the actual type of glioma (histologically and molecularly) and age of the patient, as well as various tumor specific factors such as size, location, comorbidities, etc. In the last decade we have been able to identify key molecular features that have provided us with greater insight into the behavior of these tumors, but the spectrum of treatment options remains limited. In addition, ultimate causes of death in patients with gliomas are variable and stochastic in nature. Given these complicated factors, prognostication for gliomas remains extremely difficult. This review aims to discuss prognostication in low grade versus high grade gliomas, variability in treatment of these tumors, clinical features of poor prognosis, and differences in prognostic understanding between patients, caregivers, and providers. We will also make some general recommendations where appropriate on how to approach this subject from a palliative care perspective.

Entities:  

Keywords:  Brain tumors; glioblastoma; glioma; molecular tumors

Mesh:

Year:  2020        PMID: 32787379     DOI: 10.21037/apm-20-640

Source DB:  PubMed          Journal:  Ann Palliat Med        ISSN: 2224-5820


  8 in total

Review 1.  Easing the Journey-an Updated Review of Palliative Care for the Patient with High-Grade Glioma.

Authors:  Rita C Crooms; Margaret O Johnson; Heather Leeper; Ambereen Mehta; Michelle McWhirter; Akanksha Sharma
Journal:  Curr Oncol Rep       Date:  2022-02-22       Impact factor: 5.075

2.  Dabrafenib Plus Trametinib: An Impressive Response in an Adult Patient With BRAF V600E-Mutated and Isocitrate Dehydrogenase (IDH) Wild-Type Glioma.

Authors:  Inês N Costa; Joana Reis; Jorge Pinheiro; Roberto Silva; Catarina Fernandes
Journal:  Cureus       Date:  2022-08-19

Review 3.  Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.

Authors:  Daniel Kreatsoulas; Chelsea Bolyard; Bill X Wu; Hakan Cam; Pierre Giglio; Zihai Li
Journal:  J Hematol Oncol       Date:  2022-06-11       Impact factor: 23.168

4.  Utilizing Intraoperative Navigated 3D Color Doppler Ultrasound in Glioma Surgery.

Authors:  Benjamin Saß; Mirza Pojskic; Darko Zivkovic; Barbara Carl; Christopher Nimsky; Miriam H A Bopp
Journal:  Front Oncol       Date:  2021-08-18       Impact factor: 6.244

5.  A novel protein encoded by ZCRB1-induced circHEATR5B suppresses aerobic glycolysis of GBM through phosphorylation of JMJD5.

Authors:  Jian Song; Jian Zheng; Xiaobai Liu; Weiwei Dong; Chunqing Yang; Di Wang; Xuelei Ruan; Yubo Zhao; Libo Liu; Ping Wang; Mengyang Zhang; Yunhui Liu
Journal:  J Exp Clin Cancer Res       Date:  2022-05-10

6.  The Impact of Resistance Exercise on Muscle Mass in Glioblastoma in Survivors (RESIST): Protocol for a Randomized Controlled Trial.

Authors:  Melanie R Keats; Scott A Grandy; Christopher Blanchard; Jonathon R Fowles; Heather F Neyedli; Adrienne C Weeks; Mary V MacNeil
Journal:  JMIR Res Protoc       Date:  2022-05-04

7.  Remarkable immune and clinical value of novel ferroptosis-related genes in glioma.

Authors:  Xiaoyan Gao; Jiazheng Zhao; Litao Jia; Qiushi Zhang
Journal:  Sci Rep       Date:  2022-07-27       Impact factor: 4.996

8.  Treatment with Cyclic AMP Activators Reduces Glioblastoma Growth and Invasion as Assessed by Two-Photon Microscopy.

Authors:  Krista Minéia Wartchow; Benjamin Schmid; Philipp Tripal; Andreas Stadlbauer; Michael Buchfelder; Carlos-Alberto Gonçalves; Andrea Kleindienst
Journal:  Cells       Date:  2021-03-04       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.